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Aims Impaired myocardial sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) activity is a hallmark of failing hearts, and
SERCA2a gene therapy improves cardiac function in animals and patients with heart failure (HF). Deregulation of
microRNAs has been demonstrated in HF pathophysiology. We studied the effects of therapeutic AAV9.SERCA2a
gene therapy on cardiac miRNome expression and focused on regulation, expression, and function of miR-1 in
reverse remodelled failing hearts.
Methods
and results
We studied a chronic post-myocardial infarction HF model treated with AAV9.SERCA2a gene therapy. Heart failure
resulted in a strong deregulation of the cardiac miRNome. miR-1 expression was decreased in failing hearts, but nor-
malized in reverse remodelled hearts after AAV9.SERCA2a gene delivery. Increased Akt activation in cultured cardio-
myocytes led to phosphorylation of FoxO3A and subsequent exclusion from the nucleus, resulting in miR-1 gene
silencing. In vitro SERCA2a expression also rescued miR-1 in failing cardiomyocytes, whereas SERCA2a inhibition
reduced miR-1 levels. In vivo, Akt and FoxO3A were highly phosphorylated in failing hearts, but reversed to
normal by AAV9.SERCA2a, leading to cardiac miR-1 restoration. Likewise, enhanced sodium–calcium exchanger 1
(NCX1) expression during HF was normalized by SERCA2a gene therapy. Validation experiments identified
NCX1 as a novel functional miR-1 target.
Conclusion SERCA2a gene therapy of failing hearts restores miR-1 expression by an Akt/FoxO3A-dependent pathway, which is
associated with normalized NCX1 expression and improved cardiac function.
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Introduction
Sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) drives myo-
cardial diastolic calcium (Ca2+) cytoplasmic clearance and relax-
ation after systolic Ca2+ release from the sarcoplasmic reticulum
(SR). Sarcoplasmic reticulum calcium ATPase 2a expression and
activity are impaired in failing hearts, suggesting SERCA2a as a po-
tential therapeutic target.1 Indeed, viral SERCA2a gene transfer to
failing hearts improves cardiac function and reduces arrhythmias in
vivo,1,2 and potential efficacy in heart failure (HF) patients has been
recently reported.3 MicroRNAs (miRNAs; miR) are a class of small
RNA molecules that regulate mRNA/protein expression by
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inducing transcript degradation or translational inhibition. Recent
studies have shown that miRNAs play important roles in cardiac
physiology and pathology.4,5 However, the mechanism(s) under-
pinning their regulation, expression, and functional role in
chronic HF and after SERCA2a gene therapy-mediated ventricular
reverse remodelling has never been explored.
Methods
Rat heart failure model
Rats were subjected to chronic post-myocardial infarction HF as
described previously.1 Briefly, adult male Sprague–Dawley rats weigh-
ing 250–300 g underwent proximal coronary ligation (n ¼ 17) to
induce chronic myocardial infarction. Sixteen weeks later, a subgroup
(n ¼ 9) received intravenous AAV9.SERCA2a gene therapy (see
below). Age-matched non-infarcted rats (n ¼ 8) served as healthy non-
failing controls (CTR). In the untreated HF and CTR arms, animals
were anaesthetized (2% isoflurane) and hearts were explanted at
16-week post-infarction. The left ventricular myocardium was sepa-
rated, immediately flash frozen in liquid nitrogen, and stored at
2808C until protein or RNA isolation.
Gene therapy
SERCA2a gene therapy was carried out as described previously.2 Heart
failure animals were randomized to AAV9.SERCA2a gene therapy
or placebo. Nine HF rats received a 300 mL tail vein injection of
AAV9.SERCA2a (2 × 1011 DNase-resistant particles) at least 16-week
post-infarction. We have previously reported the improvement in para-
meters of left ventricular systolic and diastolic function measured by
pressure–volume analysis after AAV9.SERCA2a gene therapy in this
model.2 Four to six weeks post-AAV9.SERCA2a injection, hearts
were explanted from HF + SERCA rats and left ventricular myocar-
dium isolated, frozen, and stored as described above.
MicroRNA profiling
MicroRNA profiling in left ventricular tissue from healthy control rats
(CTR), rats with HF 16 weeks after myocardial infarction (HF), and HF
rats treated with intravenous AAV9.SERCA2a (HF + SERCA)1 was
performed using the rat miRNome Sanger miRBase microRNA Profiler
Set (System Biosciences). Expression of 391 rat microRNAs (based on
Sanger miRbase version 14) was analysed as per the manufacturer’s
instructions.
Adult cardiomyocyte adenoviral
sarcoplasmic reticulum calcium ATPase
2a transduction
Details about the isolation and culture of adult cardiomyocytes are
given in the Supplementary material online, Methods. A subset of
freshly isolated cardiomyocytes from CTR and HF hearts were resus-
pended in M199 and transfected with adenoviral SERCA2a.GFP vector
in vitro (multiplicity of infection: 100). After 48 h in culture with
Ad.SERCA2a.GFP, with efficacy of in vitro transduction confirmed by
GFP fluorescence, myocytes were spun down at 300g for 5 min, resus-
pended in 350 mL Trizol reagent, and frozen at 2808C for polymerase
chain reaction (PCR) studies.
Measurement of calcium transients
Adult cardiomyocytes were loaded with Fluo-4AM (1 mmol/L) with
0.16% pluronic acid F127 to visualize intracellular Ca2+. Myocytes
were spun down at 300 RPM, the supernatant removed, and the
pellet resuspended in 1 mL of Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco BRL, Life Technologies) + 100 mmol/L EGTA to
wash. This was repeated twice and then the cells were resuspended
in 2 mL of DMEM + EGTA and left for 30 min at room temperature
(RT) to allow de-esterification of the fluorescent indicator. The cells
were continuously superfused at a rate of 2–3 mL/min with normal
Tyrode’s (NT) solution (378C) containing (in mmol/L): NaCl 140,
KCl 6, MgCl2 1, CaCl2 2, glucose 10, and HEPES 10, pH 7.40+0.01.
Cells were field-stimulated at 1 Hz using a pair of platinum electrodes.
To assess the SR Ca2+ content, cells were superfused (15 mL/min)
with NT containing 10 mmol/L caffeine producing a fast application
of the substance—a ‘caffeine spritz’. Caffeine releases SR Ca2+, so
the size of the caffeine-induced transient can be used as a qualitative
index of the SR Ca2+ content. The acquisition software pCLAMP
was used and data analysed with Clampfit.
The effects of thapsigargin on Ca2+ transients of cardiomyocytes
were observed after cells had been preloaded with fura-2 (1.5 mM dis-
solved in DMSO stock solution). Thapsigargin (100 mM) dissolved in car-
diomyocyte solution (117 mM NaCl, 5.7 mM KCl, 1.2 mM NaH2PO4,
0.66 mM MgSO4.7H2O, 10 mM glucose, 5 mM Na-pyruvate, 10 mM
creatine, 20 mM HEPES, and 1.25 mM CaCl2.2H2O) was flushed into
the cell chamber while measuring continuously fluorescence.
Cells were alternately quiescent and stimulated (1 Hz) for periods of
1–2 min. In order to block thapsigargin effects, cells were pre-
incubated with the Ca2+ scavenger 1,2-bis(o-aminophenoxy)ethane-
N,N,N′,N′-tetraacetic acid (BAPTA; 100 mM) for 5 min before changing
to thapsigargin/BAPTA solution.
RNA and protein detection
RNA from frozen heart tissue or from cell cultures was isolated using
TRIzol reagent as per the manufacturer’s instructions. miR-1 expres-
sion was quantified by using TaqMan assays (Applied Biosystems)
and normalized to the small RNA Rnu6b as a control. Messenger
RNA expression was quantified by the SYBR-green method using
the following primers: sodium-calcium exchanger 1 (NCX1)—
5′-GTG GAG GTC TGG GAA GGA TT-3′ (forward) and 5′-GCT
TCC TCG TCA TCT TGG TC-3′ (reverse); GAPDH—
5′-GAAGGGCTCATGACCACAGT-3′ (forward) and 5′-GGA TGC
AGG GAT GAT GTT CT-3′ (reverse). Protein from heart tissue or
cultured cells was isolated using cell lysis buffer (Cell Signaling) and
separated on a 10% SDS–PAGE and protein expression was detected
by Western blotting using specific antibodies stated in Supplementary
material online, Methods.
Immunofluorescence microscopy
Adult rat cardiomyocytes were transfected with pre-miR-1 or
anti-miR-1 using lipofectamine and treated with or without phenyleph-
rine (PE) for 48 h. After the treatment, cells were fixed in 4% parafor-
maldehyde for 15 min at RT followed by 3× washes with PBS for
5 min each. Cells were then blocked with 5% donkey serum (in PBS)
for 30 min at RT and incubated overnight in the presence of primary
antibody against a-actinin (1:600 in blocking buffer). At the end of in-
cubation, cells were 3× washed with PBS incubated with FITC-labelled
secondary antibody (1:500 in blocking buffer, 1 mL/mL DAPI from
5 mg/mL stock) for 30 min at RT, washed again 3× with PBS, and
then observed under the fluorescence microscope.
Luciferase gene reporter assay
Targeting of NCX1 3′UTR by miR-1 was validated by the luciferase re-
porter assay. The putative target sequence in the NCX1 3′UTR was
cloned into pMIR-REPORT vector (Ambion) between SpeI and
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HindIII sites using 5′-AAA ACT AGT GCA ACT CCT GAG TGG AAA
GG-3′ (forward) and 5′-AAA AAG CTT CAG GGA GGC TCA GAG
AAG TG-3′ (reverse) primers. Luciferase reporter (0.2 mg/well) was
co-transfected along with pre-miR-1 (100 nM) and
b-galactosidase-expressing plasmid (0.2 mg/well) into HEK293 cells
using lipofectamine (Invitrogen) in a 48-well plate. Luciferase and
b-galactosidase enzyme activity was measured after 48 h of transfec-
tion and luciferase values were normalized to b-galactosidase readings.
Data analysis
Statistical analyses were performed by one-way ANOVA followed by
Bonferroni’s multiple comparison test (for comparison of more than
two groups) or Student’s t-test (for comparison of two groups)
(GraphPad Prism). Data are given as mean+ SD or mean+ SEM as
indicated in the respective legends. A P-value (two-sided) of ,0.05
was considered significant.
Results
Sarcoplasmic reticulum calcium ATPase
2a gene therapy restores muscle-specific
miR-1 expression in failing hearts
We previously reported a rat model of advanced HF 16-week
post-myocardial infarction6 and rescue of the HF phenotype
after AAV9.SERCA2a gene therapy.1 Specifically, SERCA2a
restored systolic and diastolic function, reduced arrhythmia gener-
ation, and normalized cardiomyocyte Ca2+ transients and SR
load–leak relationships.1 Here, we examined left ventricular
samples from the same study, given the profound reverse remodel-
ling changes observed, to explore whether reversal of myocardial
miRNome changes observed in failing hearts could account for
some of these beneficial changes previously reported. We profiled
miRNA expression of left ventricular tissue from rats with HF with
(HF + SERCA) and without (HF) AAV9.SERCA2a gene therapy
(Figure 1A). Fifty-two miRNAs were deregulated during chronic
HF (Figure 1A and B; see Supplementary material online, Table S1).
Of importance, array results detected normalization of 20 (38.4%)
deregulated miRNAs by SERCA2a gene therapy. In particular,
among the normalized miRNAs, only miR-1 was cardiomyocyte-
specific, and this was validated by qRT–PCR analyses (Figure 1B).
We thus focused on miR-1 and next determined the potential
molecular mechanisms responsible for this observation.
Akt activation negatively regulates
cardiomyocyte miR-1 expression in vitro
and in failing hearts in vivo, and this is
reversed in sarcoplasmic reticulum
calcium ATPase 2a treated hearts
To assess successful miR-1 regulation and function in a cardiomyo-
cyte in vitro model, we first measured miR-1 expression in adult rat
cardiomyocytes 48 h after PE treatment. miR-1 expression was
down-regulated after PE treatment (Figure 2A). miR-1 overexpres-
sion significantly attenuated PE-induced cardiomyocyte hyper-
trophy, demonstrating functionality of miR-1 modulation in vitro
(Figure 2B and C; efficiency of pre- or anti-miR-1 molecules to
modulate miR-1 expression in adult rat cardiomyocytes is shown
in Figure 2D and E, respectively). We next assessed the upstream
miR-1 regulation in this cardiomyocyte in vitro model.
The miR-1 promoter has consensus sequences for the FoxO3a
transcription factor and a dominant active form of FoxO3A (non-
phosphorylated) up-regulates miR-1 in isolated cardiomyocytes.7
Transcriptional activity of FoxO3a depends on its phosphorylation
status, and once phosphorylated, e.g. by the serine/threonine
protein kinase Akt, FoxO3a is shifted from the nucleus to the
cytosol.8 We detected a strong increase in phosphorylated
(active) Akt levels in failing hearts, which were completely
restored to normal levels after SERCA2a gene therapy
(Figure 3A and B). Consistent with this, expression of phospho-
FoxO3A paralleled phospho-Akt levels (Figure 3A and B). To
examine whether Akt activation leads to FoxO3A phosphoryl-
ation, cultured cardiomyocytes were treated with the Akt activa-
tor platelet-derived growth factor (PDGF). This led to increased
Akt and FoxO3A phosphorylation based on time-dependency
studies (Figure 3C). To verify whether FoxO3a phosphorylation
leads to decreased nuclear FoxO3A content, cultured cardiomyo-
cytes were treated with PDGF, and cytosolic and nuclear fractions
separately investigated for FoxO3a levels. Indeed, Akt activation
resulted in reduced nuclear FoxO3a content in cardiomyocytes
(Figure 3D). Pharmacological SERCA2a inhibition using thapsigargin
also resulted in increased Akt and FoxO3A phosphorylation in
cultured cardiomyocytes (Figure 3E). Under these conditions,
thapsigargin-mediated SERCA2a inhibition led to a significant re-
pression of miR-1 (Figure 3F). These results suggest that Akt-
mediated phosphorylation of FoxO3A results in its exclusion
from the nucleus and subsequent down-regulation of miR-1 in
failing cardiomyocytes, and this is reversed by SERCA2a gene
therapy.
To test the influence of SERCA2a gene therapy on miR-1
expression directly in cardiomyocytes, we performed further in
vitro studies. We acutely overexpressed SERCA2a in freshly
isolated cardiomyocytes from adult rats with normal and failing
hearts using an adenoviral vector. There was no significant effect
of SERCA2a transduction in healthy cultured cardiomyocytes on
miR-1 expression. However, miR-1 expression was reduced in
failing cardiomyocytes and normalized upon SERCA2a transduc-
tion (Figure 3G). To further assess the effects of Ca2+ availability
on cardiac miR-1 expression, we treated adult healthy cardiomyo-
cytes with the SERCA2a inhibitor thapsigargin, which raised
diastolic Ca2+ levels and also resulted in reduced miR-1 expres-
sion levels. This thapsigargin-dependent miR-1 reduction could
be attenuated by concomitant treatment with the cell membrane
permeable Ca2+ scavenger BAPTA (Figure 3H and I ). As high
diastolic intracellular Ca2+ levels activate the Ca2+/calmodulin-
dependent protein kinase kinase (CaMKK), which further contri-
butes to Akt activation,9 we additionally tested involvement of
CaMKK in Ca2+-mediated miR-1 modulation. Indeed, miR-1
down-regulation upon SERCA inhibition was attenuated by
CaMKK inhibition (Figure 3K). In summary, the combined results
from our in vivo and in vitro experiments suggest that SERCA2a
gene therapy especially in failing cardiomyocytes with high intracel-
lular Ca2+ concentrations normalizes miR-1 expression by
normalization of cellular Ca2+ concentrations and an Akt–
FoxO3a-dependent mechanism.
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miR-1 targets the sodium–calcium
exchanger (NCX1)
The sodium–calcium exchanger NCX1 (also known as SLC8A1) is
frequently up-regulated during HF.10 Cardiac overexpression of
NCX1 results in the depression of contractile function,11
whereas NCX1 inhibition restores Ca2+ handling in cardiomyo-
cytes.12 During chronic HF, NCX1 up-regulation may serve as a
compensatory mechanism to improve diastolic Ca2+ clearance in
the setting of reduced SERCA2a levels and/or activity. However,
the mechanism for this compensatory response is currently
unknown. Within the 3′UTR of rat NCX1 gene, we identified a pu-
tative miR-1-binding sequence that is highly conserved throughout
evolution (Figure 4A). miR-1 overexpression in cultured cardiomyo-
cytes silenced NCX1 protein expression (Figure 4B). To validate
NCX1 as a bona fide miR-1 target, we cloned a 241 nt length
NCX1 3′UTR harbouring the miR-1-binding site to a luciferase
coding sequence. Indeed, luciferase activity was decreased by
more than 60% when miR-1 was overexpressed, confirming the
direct targeting of NCX1 by miR-1 (Figure 4C).
Next, we compared NCX1 protein expression in HF and HF +
S hearts and found that consistent with miR-1 down-regulation, its
target NCX1 was up-regulated in failing hearts but normalized
after SERCA2a gene therapy (Figure 4D). To investigate whether in-
hibition of miR-1 (and subsequent NCX1 up-regulation) would
enhance Ca2+ extrusion from the cell, anti-miR-1-transfected car-
diomyocytes were treated with a caffeine pulse to rapidly unload
SR Ca2+ stores and challenge the cardiomyocyte Ca2+ extrusion
systems, including NCX1. Decay of the caffeine-induced cytoplas-
mic Ca2+ transient was significantly faster in miR-1-silenced cells
compared with scrambled control-transfected cells, showing a
direct functional link of altered miR-1 expression to cardiomyocyte
Ca2+ handing (Figure 4E).
In conclusion, we here propose an explanation of the beneficial
effects of SERCA2a gene therapy partly based on normalized Ca2+
Figure 1 (A and B) miRNA expression profiling in pooled RNA samples from left ventricular tissue from controls (CTR), rats with heart
failure, and heart failure rats after sarcoplasmic reticulum calcium ATPase 2a gene therapy (HF + SERCA). MicroRNAs deregulated greater
than three-fold (HF vs. CTR) are depicted in green and the effects on individual microRNA expression up on sarcoplasmic reticulum calcium
ATPase 2a gene therapy in shown in red. (B) Validation of miR-1 expression in left ventricular tissue from controls (CTR), rats with heart
failure, and heart failure rats after sarcoplasmic reticulum calcium ATPase 2a gene therapy (HF + SERCA). n ¼ 6–10 experiments/animals
per group for validation experiments. Triplicate polymerase chain reactions for each animal/sample were used. Data are mean + SD. *P, 0.05.
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homeostasis and an Akt–FoxO3a-dependent mechanism leading
to restored miR-1 expression (Figure 5).
Discussion
In this report, we demonstrate that reverse remodelling by thera-
peutic SERCA2a gene delivery normalizes expression of a number
of miRNAs including myocyte-specific miR-1 within the failing
heart. miR-1 is one of the most abundant miRNAs in the heart13
and regulates several target proteins that function as transcription
factors,14,15 receptor ligands,16,17 apoptosis regulators,18 and ion
channels.19 Although miR-1 has been found to be overexpressed
in individuals with coronary artery disease19 and to exacerbate
arrhythmogenesis when overexpressed,19,20 several studies indi-
cate that miR-1 plays a protective role against cardiac hypertrophy
or HF by regulating several hypertrophy-associated genes including
HCN2,21 calmodulin 1, 2, Mef2a,15 IGF1, and IGF1R.7 miR-1 was
previously found to be down-regulated in different models of
cardiac hypertrophy and failure including transverse aortic con-
stricted mice or transgenic mice with selective cardiac overexpres-
sion of a constitutively active mutant of the Akt kinase.22
We found SERCA2a-mediated restoration of miR-1 expression
to be dependent on an Akt–FoxO3a-regulated mechanism,
which led to a normalization of cardiac sodium–calcium exchanger
Figure 2 (A) miR-1 expression 48 h after treatment of adult rat cardiomyocytes with phenylephrine (PE, 100 mM) or placebo (CTR). (B)
Adult rat cardiomyocytes were transfected with scrambled control, pre-miR-1, or anti-miR-1 and treated with phenylephrine (100 mM) as indi-
cated. Cells were fixed with paraformaldehyde and stained for a-actinin. (C) Cardiomyocyte surface area was measured using NIS-Elements BR
software (version 3.2). Cell size of 13–15 cardiomyocytes was counted for each condition. miR-1 expression in adult rat cardiomyocytes 48 h
after transfection with scrambled control, pre-miR-1 (D), or anti-miR-1 (E) (each 100 nM). RNU6b served as a housekeeping control.
**P, 0.01, ***P, 0.001.
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Figure 3 (A and B) Akt, p-Akt, FoxO3a, and p-FoxO3a protein expression in left ventricular tissue from controls (CTR), rats with heart
failure, and heart failure rats after sarcoplasmic reticulum calcium ATPase 2a gene therapy (HF + SERCA). See Figure 4D for housekeeping
control GAPDH. (C) Time course of p-Akt and p-FoxO3a expression after Akt activation (PDGF, 100 ng/mL, 24 h) in cultured cardiomyocytes.
(D) FoxO3a total levels in cytosolic and nucleic fractions of adult cardiomyocytes 24 h after Akt stimulation (PDGF, 100 ng/mL). Gapdh (cyto-
solic localization) and Sp1 (nuclear localization) levels served as controls. (E) Time course of p-Akt and p-FoxO3a expression and miR-1 ex-
pression (F) after sarcoplasmic reticulum calcium ATPase inhibition (thapsigargin, 100 mM) in cultured cardiomyocytes. (G) Effects of viral
sarcoplasmic reticulum calcium ATPase 2a transduction of freshly isolated adult cardiomyocytes from healthy control rats (Healthy) and
rats with heart failure due to myocardial infarction. (H ) Typical examples of intracellular Ca2+ levels (inferred from the ratio of fluorescence
emitted at 510 nm after excitation at 340 nm and 380 nm) immediately after thapsigargin (TSG) addition in stimulated (1 Hz) adult rat cardi-
omyocytes. (I ) miR-1 expression levels in adult rat cardiomyocytes treated with the sarcoplasmic reticulum calcium ATPase inhibitor thapsi-
gargin (TSG, 100 mM, 24 h) or with TSG and the calcium scavenger BAPTA (100 mM, 24 h) or (K ) TSG and the calmodulin-dependent
protein kinase kinase inhibitor STO609 (10 mM, 24 h). n ¼ 3–10 experiments/animals per group. Data are mean + SEM. *P, 0.05;
**P, 0.01; ***P, 0.001; #P ¼ 0.06.
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NCX1 expression. Thus, the beneficial effects of SERCA2a gene
therapy are at least in part mediated by normalization of miR-1.
Indeed, the Akt–FoxO3a pathway seems to play important role
in regulation of miR-1 levels. Although acute activation of Akt is
cardio-protective in vitro and in vivo due to its ability to inhibit apop-
tosis,23,24 chronic Akt activation in the heart has been shown to be
detrimental25,26 and higher levels of phosphorylated-Akt have been
reported in chronically failing human hearts.27 In this study, we show
that Akt phosphorylation in chronic failing hearts is accompanied by
FoxO3a phosphorylation, which is responsible for decreased miR-1
expression. This miR-1 repression in failing hearts could be normal-
ized by AAV9.SERCA2a treatment via reversal of the phosphory-
lated Akt–FoxO3a axis. In vitro, we showed that acute SERCA2a
overexpression normalized miR-1 levels in cardiomyocytes from
failing hearts, while miR-1 levels in healthy cardiomyocytes remained
unchanged. Conversely, acute selective SERCA2a inhibition lowered
miR-1 expression in a manner dependent upon the rise in diastolic
Ca2+ and CaMKK activation. These observations are in agreement
Figure 4 (A) Evolutionarily conserved miR-1 binding sites in the 3′UTR of the NCX1 gene. (B) NCX1 protein expression 48 h after trans-
fection of adult cardiomyocytes with miR-1 precursor molecules (pre-miR-1; 100 nM) or scrambled controls (Scr, 100 nM). (C) Luciferase gene
reporter assay of a 3′UTR region of the NCX1 gene harbouring an miR-1-binding site and co-transfection with miR-1 or scrambled controls
(Scr). (D) NCX1 protein expression in left ventricular tissue from controls (CTR), rats with heart failure, and heart failure rats after sarcoplas-
mic reticulum calcium ATPase 2a gene therapy (HF + SERCA). (E) Time constant of decay (t) of caffeine transients in cardiomyocytes trans-
fected with miR-1 inhibitors (anti-miR-1) or scrambled controls (Scr). n ¼ 3–8 experiments/animals per group. Data are mean + SEM.
*P, 0.05; ***P, 0.001.
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with a direct effect of SERCA2a levels and activity upon miR-1 ex-
pression levels, rather than the miR-1 recovery observed in vivo
being solely an indirect reflection of beneficial reverse remodelling.
Indeed, this recovery of miR-1 expression may provide one explan-
ation for the beneficial effects of SERCA2a gene therapy in rescuing
advanced chronically failing hearts.
Next to SERCA2a silencing, NCX1 up-regulation during HF is
frequently observed28–30 and this combination is proarrhyth-
mic.1,31 In the present study, we identified NCX1 as a direct
miR-1 target and found that selectively reducing miR-1 levels in
adult cardiomyocytes resulted in accelerated cytoplasmic Ca2+
removal. Sarcoplasmic reticulum calcium ATPase 2a-mediated nor-
malization of cardiac miR-1 expression levels may explain normal-
ization of NCX1 levels via an Akt–FoxO3a–miR-1-dependent
negative feedback circuit. Hence, two critical proteins for cardio-
myocyte diastolic Ca2+ clearance, SERCA2a and NCX, are intim-
ately regulated with SERCA2a activity directly influencing NCX
expression in a reciprocal manner via the Akt–FoxO3a–miR-1
pathway. Therapeutically, this SERCA2a–miR-1-dependent mech-
anism of NCX1 down-regulation in failing hearts may contribute
to the reduced incidence of delayed after depolarizations and
arrhythmias previously reported after SERCA2a gene therapy.1
This may also aid the contractile improvements, as improving the
SERCA2a:NCX ratio, in the context of restored SERCA2a levels,
will allow more Ca2+ to be re-sequestered into the SR and
available for subsequent systolic release, without influencing the
kinetics of relaxation which are predominantly SERCA2a-
dependent. The influence and effects resulting from the normaliza-
tion of the other non-exclusively myocyte expressed miRNAs
observed during SERCA2a gene therapy on cardiac reverse
remodelling remains to be determined.
In conclusion, our results show that miR-1 is down-regulated in
a chronic HF model and its expression is restored to normal levels
during reverse remodelling by SERCA2a gene therapy, which was
mediated at least in part by modulation of intracellular Ca2+ hand-
ling and an Akt–FoxO3a-dependent mechanism.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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